May 12 (Reuters) - China's Jiangsu Hengrui Pharmaceuticals 1276.HK 600276.SS said on Tuesday it has struck global strategic collaboration and licensing deal with U.S. drugmaker Bristol Myers Squibb BMY.N to develop 13 early‑stage oncology, hematology and immunology programmes, with potential milestone payments of up to $15.2 billion.